查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1169169

先天性高胰島素血症治療市場：按疾病類型、藥物類型（二氮秦,奧曲□,胰高血糖素,硝苯地平等）,給藥途徑,分銷渠道,地區-規模,份額,展望,機會分析2022-2030

Congenital Hyperinsulinism Treatment Market, by Disease Type, Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other, Route of Administration, Distribution Channel, & Region - Size, Share, Outlook, & Opportunity Analysis, 2022 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 190 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

先天性高胰島素血症 (CHI)，也稱為高胰島素血症性低血糖症，是一種罕見的內分泌疾病，主要影響新生兒、嬰兒和兒童，並導致腦損傷和嚴重低血糖症。是最常見的原因 胰腺BETA細胞胰島素分泌過多導致KATP通道基因發生基因突變（ABCC8、KCNJ11、HNF4A、HNF1A、HADH、UCP2或GLUD1、GCK、SLC16A1的激活突變），導致先天性超敏反應。據說會引起胰島素血症. 由於對大腦造成永久性損傷的風險很高，CHI 需要及時診斷和立即治療，以預防癲癇、腦癱和神經發育障礙等並發症。 根據國家罕見疾病組織數據庫，在大多數患有 HI 的國家中，每 25,000 人中就有 1 人到 50,000 人中有 1 人會在出生後的頭幾個月出現低血糖症。 低血糖可引起多種症狀，從煩躁、嗜睡、過度飢餓和心率加快等常見症狀到癲癇發作和昏迷等更嚴重的症狀。 有些是短暫的，有些是由於遺傳缺陷而終生的，並且根據疾病的形式有不同的原因。 在早產兒中，過多的胰島素會導致低血糖。 胰島素分泌不足的原因尚不清楚，但可持續數天至數月。

市場動態

包括 Zealand Pharma A/S、Hanmi Pharm.Co.、Eli Lilly and Company 在內的多家主要參與者正在為治療先天性高胰島素血症的新型治療方案的開發進行持續研究，預計這將推動期間全球先天性高胰島素血症藥物市場。 例如，2019 年 5 月，生物技術公司 Zealand Pharma A/S 啟動了 Dasiglucagon 的 3 期臨床試驗。 該試驗旨在評估 dasiglucagon 治療先天性高胰島素血症兒科患者的療效和安全性。 該研究預計將於 2022 年 12 月完成。 Dasiglucagon 是胰高血糖素的□類似物，設計有七個氨基酸取代以消除原纖維形成和□聚集。

這項研究的主要特點

  • 本報告對全球先天性高胰島素血症藥物市場進行了深入分析，揭示了以 2021 年為基準年的預測期（2022-2030 年）的市場規模和復合年增長率 (CAGR%))。
  • 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
  • 它還提供重要的見解，例如市場驅動因素、制約因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略。
  • 根據以下參數對全球先天性高胰島素血症治療市場的主要參與者進行了介紹 - 公司亮點、產品組合、主要亮點、財務業績和戰略。
  • 本研究涵蓋的主要公司包括 Zealand Pharma A/S、Eli Lilly and Company、Xeris Pharmaceuticals, Inc.、Rezolute, Inc.、Hanmi Pharm.Co., Ltd.、Fresenius Kabi AG 和 Eiger BioPharmaceuticals。 , Crinetics Pharmaceuticals, Inc., AmideBio, LLC, Jolly Healthcare, e5 Pharma, LLC, Merck & Co., Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals, Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.
  • 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
  • 《全球先天性高胰島素血症治療市場》報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
  • 利益相關者可以通過用於分析全球先天性高胰島素血症治療市場的各種戰略矩陣來促進決策制定。

內容

第 1 章目的和先決條件

  • 調查目的
  • 先決條件
  • 縮寫說明

第2章市場展望

  • 報告內容
    • 市場定義和範圍
  • 執行摘要
    • 按疾病類型劃分的市場概況
    • 市場概況：按藥物類型
    • 按給藥途徑劃分的市場概況
    • 市場概況：按銷售渠道
    • 市場概況：按地區
  • 連貫機會圖 (COM)

第 3 章市場動態、法規和趨勢分析

  • 市場動態
    • 司機
    • 約束因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 近期趨勢
  • 收購和合作場景
  • 監管場景
  • 定價分析
  • 害蟲分析

第 4 章先天性高胰島素血症藥物的全球市場：按疾病類型分類，2017-2030 年。

  • KATP-HI
  • 廣東粵海
  • GK-HI
  • 其他（SCHAD HI、HNF4A/HNF1A HI 等）

第 5 章先天性高胰島素血症藥物的全球市場：按藥物類型分列，2017-2030

  • 二氮秦
  • 奧曲□
  • 胰高血糖素
  • 硝苯地平
  • 其他（西羅莫司、氯塞秦等）

第 6 章先天性高胰島素血症藥物的全球市場：按給藥途徑，2017-2030

  • 口語
  • 腸外

第 7 章先天性高胰島素血症藥物的全球市場：按分銷渠道，2017-2030

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第 8 章先天性高胰島素血症藥物的全球市場：按地區劃分，2017-2030

  • 北美
  • 美國
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地區
  • 歐洲
  • 英國
  • 德國
  • 意大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 東盟
  • 澳大利亞
  • 韓國
  • 其他亞太地區
  • 中東
  • 海灣合作委員會
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中非
  • 南非

第9章競爭格局

  • Zealand Pharma A/S
  • Eli Lilly and Company
  • Xeris Pharmaceuticals, Inc.
  • Rezolute, Inc.
  • Hanmi Pharm.Co., Ltd.
  • Fresenius Kabi AG
  • Eiger BioPharmaceuticals.
  • Crinetics Pharmaceuticals, Inc.
  • AmideBio,LLC
  • Jolly Healthcare
  • e5 Pharma, LLC.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Amphastar Pharmaceuticals.Inc,
  • USV Private Limited.
  • Teva Pharmaceutical Industries Ltd.

第10章 章節

  • 調查手法
  • 關於出版社
簡介目錄
Product Code: CMI5329

Congenital hyperinsulinism(CHI) also called as hyperinsulinemic hypoglycemia, a rare endocrine condition that causes low blood glucose levels and occurs mainly in newborn babies, infants and children leading to permanent brain injury and is most frequent cause of severe hypoglycemia. Over secretion of insulin by beta cells in pancreas leads to gene mutation in KATP channel genes (ABCC8 and KCNJ11, HNF4A, HNF1A, HADH, and UCP2 or activating mutations of GLUD1, GCK, and SLC16A1) that cause congenital hyperinsulinism. There is significant risk of permanent brain damage in CHI, hence it is necessary to make a prompt diagnosis and obtain immediate management of the disease to prevent complications such as epilepsy, cerebral palsy and neurodevelopmental deficits. According to the National Organization for Rare Disorders database, approximately 1/25,000 to 1/50,000 HI births occurs in most of the countries including HI develop hypoglycemia during the first month of life. Irritability, sleepiness, excessive hunger, rapid heart rate are common symptoms that occurs while more severe symptoms, such as seizures and coma occur. There are many causes of congential hyperinsulinism based on different forms of the disease for example there are transient forms while some are due to genetic defects and persist for life. Prematurely born babies sometimes, develop hypoglycemia due to excessive insulin secretion. The cause of this inappropriate insulin secretion is still not clear, but it can last a few days to months.

Market Dynamics

Ongoing research for development of novel therapeutic options for the treatment of congenital hyperinsulinismby various key players such as Zealand Pharma A/S, Hanmi Pharm.Co., Ltd., Eli Lilly and Company is anticipated to drive the growth of global congenital hyperinsulinismtreatment market over the forecast period. For instance, in May 2019, Zealand Pharma A/S, a biotechnology company initiated Phase 3 clinical trial of Dasiglucagon. The study aims to assess the efficacy and safety of Dasiglucagon for the treatment of pediatric patients with congenital hyperinsulinism. The study is estimated to be completed by December 2022. Dasiglucagon is a peptide analogue of glucagon consisting 7 amino acid substitutions engineered to eliminate fibril formation as well as peptide aggregation.

Key features of the study:

  • This report provides an in-depth analysis of the global congenital hyperinsulinism treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global congenital hyperinsulinism treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio, LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global congenital hyperinsulinism treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global congenital hyperinsulinism treatment market

Detailed Segmentation:

  • Global Congenital Hyperinsulinism Treatment Market, By Disease Type:
    • KATP-HI
    • GDH-HI
    • GK-HI
    • Other (SCHAD HI, HNF4A/HNF1A, etc.)
  • Global Congenital Hyperinsulinism Treatment Market, By Drug Type:
    • Diazoxide
    • Octerotide
    • Glucagon
    • Nifedipine
    • Other (Sirolimus, Chlorothiazide, etc.)
  • Global Congenital Hyperinsulinism Treatment Market, By Route of Administration:
    • Oral
    • Parental
  • Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Congenital Hyperinsulinism Treatment Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Region/Country
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Hanmi Pharm.Co., Ltd.,
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Zealand Pharma A/S
    • Eli Lilly and Company
    • Xeris Pharmaceuticals, Inc.,
    • Rezolute, Inc.,
    • Fresenius Kabi AG
    • Eiger BioPharmaceuticals.,
    • Crinetics Pharmaceuticals, Inc.,
    • AmideBio,LLC
    • Jolly Healthcare
    • e5 Pharma,LLC
    • Merck & Co., Inc.
    • Novo Nordisk A/S
    • Amphaster Pharmaceuticals, Inc.
    • USV Private Limited
    • Teva Pharmaceutical Industries

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Disease Type
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Recent Developments
  • Acquisitions and Partnerships Scenario
  • Regulatory Scenario
  • Pricing Analysis
  • PEST Analysis

4. Global Congenital Hyperinsulinism Treatment Market, By Disease Type, 2017-2030,(US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • KATP-HI
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • GDH-HI
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • GK-HI
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Other (SCHAD HI, HNF4A/HNF1A HI, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

5. Global Congenital Hyperinsulinism Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Diazoxide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Octreotide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Glucagon
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Nifedipine
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Other (Sirolimus, Chlorothiazide, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Congenital Hyperinsulinism Treatment Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Overview
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Congenital Hyperinsulinism Treatment Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • UK
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Zealand Pharma A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
  • Xeris Pharmaceuticals, Inc.
  • Rezolute, Inc.
  • Hanmi Pharm.Co., Ltd.
  • Fresenius Kabi AG
  • Eiger BioPharmaceuticals.
  • Crinetics Pharmaceuticals, Inc.
  • AmideBio,LLC
  • Jolly Healthcare
  • e5 Pharma, LLC.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Amphastar Pharmaceuticals.Inc,
  • USV Private Limited.
  • Teva Pharmaceutical Industries Ltd.

10. Section

  • Research Methodology
  • About Us